Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
| Autor: | Michael Wang, Alessandro Corso, Jerome B. Zeldis, Donna M. Weber, Jean Luc Harousseau, Andrew Spencer, Marta Olesnyckyj, Meletios A. Dimopoulos, Zhinuan Yu, Michel Attal, Christine Chen, Robert Knight |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Urology Salvage therapy Dexamethasone Antineoplastic Combined Chemotherapy Protocols medicine Humans Adverse effect Lenalidomide Multiple myeloma Aged Retrospective Studies Very Good Partial Response Aged 80 and over Salvage Therapy business.industry Hematology Middle Aged medicine.disease Surgery Thalidomide Treatment Outcome Clinical Trials Phase III as Topic Corticosteroid Original Article Female business Multiple Myeloma medicine.drug |
| Popis: | Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. Design and Methods Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1–4, 9–12, and 17–20 for four cycles, and only on days 1–4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. Results At the time of unblinding, 32% of patients had achieved a complete or very good partial response and 28% had a partial response. Half (50.5%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|